Quarterly ResultMay 14, 2026, 07:16 AM
Invivyd Q1 Revenue $13.7M, +22%; VYD2311 Data in Q3 2026
AI Summary
Invivyd, Inc. reported its first quarter 2026 financial results, with PEMGARDA net product revenue growing 22% year-over-year to $13.7 million. The company's net loss increased to $41.4 million, primarily due to higher R&D expenses for the VYD2311 DECLARATION pivotal clinical trial, which achieved full initial enrollment and is now expected to deliver top-line data in Q3 2026. Invivyd also announced positive in vitro neutralization data for pemivibart and VYD2311 against the SARS-CoV-2 BA.3.2.2 variant and initiated development for new monoclonal antibody candidates for measles and RSV.
Key Highlights
- PEMGARDA net product revenue reached $13.7 million in Q1 2026, a 22% increase from Q1 2025.
- Cash and cash equivalents stood at $184.2 million as of March 31, 2026, with an additional ~$20 million raised in April 2026.
- R&D expenses increased to $30.7 million in Q1 2026, up from $10.6 million in Q1 2025, due to VYD2311 clinical trials.
- SG&A expenses rose to $25.1 million in Q1 2026, compared to $16.8 million in Q1 2025, driven by personnel and marketing costs.
- Net loss for Q1 2026 was $41.4 million, compared to $16.3 million in Q1 2025.
- DECLARATION pivotal trial enrollment was completed in March 2026, with top-line data anticipated in Q3 2026.
- IDMC recommended reducing VYD2311 post-dose monitoring time from two hours to 30 minutes.
- Invivyd advanced VMS063, a measles monoclonal antibody candidate, towards IND readiness in late 2026.
- Invivyd launched the "Antibodies for Any Body" national education campaign with Lindsey Vonn.
Price Impact
More from IVVD